A retrospective analysis of patients (n=95) with advanced NSCLC found that patients who received anti-PD-1 antibody, nivolumab, between 9:27 AM and 12:54 PM nearly quadrupled their PFS compared to those who received nivolumab between 12:55 PM and 5:14 PM [11.3 months PFS, 95% CI (5.5-17.1), P < 0.001 compared to 3.1 months PFS 95% CI (1.5-4.6), P < 0.001] (94). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.